155 related articles for article (PubMed ID: 38495131)
21. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives.
Worch J; Rohde M; Burkhardt B
Pediatr Hematol Oncol; 2013 Sep; 30(6):465-83. PubMed ID: 23570584
[TBL] [Abstract][Full Text] [Related]
22. Patient parameters and response after administration of rituximab in pediatric mature B-cell non-Hodgkin lymphoma.
Bethke M; Varga G; Weinhage T; Sabharwal H; Mellgren K; Randau G; Rolfing M; Wittkowski H; Foell D; Michgehl U; Burkhardt B
Pediatr Blood Cancer; 2022 Apr; 69(4):e29514. PubMed ID: 34939314
[TBL] [Abstract][Full Text] [Related]
23. Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.
Cheah CY; Belada D; Fanale MA; Janikova A; Czucman MS; Flinn IW; Kapp AV; Ashkenazi A; Kelley S; Bray GL; Holden S; Seymour JF
Lancet Haematol; 2015 Apr; 2(4):e166-74. PubMed ID: 26687959
[TBL] [Abstract][Full Text] [Related]
24. [Clinical analysis of 60 children with anaplastic large cell lymphoma in a single center].
Wang M; Mi Q; Yuan Q; Han YL; Wang JM; Luo CY; Pan C; Tang JY; Gao YJ
Zhonghua Er Ke Za Zhi; 2021 Oct; 59(10):824-829. PubMed ID: 34587677
[No Abstract] [Full Text] [Related]
25. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
26. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Osumi T; Mori T; Fujita N; Saito AM; Nakazawa A; Tsurusawa M; Kobayashi R
Pediatr Blood Cancer; 2016 Oct; 63(10):1794-9. PubMed ID: 27314926
[TBL] [Abstract][Full Text] [Related]
27. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
28. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Cvetković RS; Perry CM
BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence.
Attias D; Weitzman S
Curr Opin Pediatr; 2008 Feb; 20(1):17-22. PubMed ID: 18197034
[TBL] [Abstract][Full Text] [Related]
30. Treatment Strategies and Prognostic Factors of Primary Gastric Diffuse Large B Cell Lymphoma: A Retrospective Multicenter Study of 272 Cases from the China Lymphoma Patient Registry.
Yang H; Wu M; Shen Y; Lei T; Mi L; Leng X; Ping L; Xie Y; Song Y; Cen X; Zhu J
Int J Med Sci; 2019; 16(7):1023-1031. PubMed ID: 31341416
[No Abstract] [Full Text] [Related]
31. [Report of Chinese Children's Cancer Group acute lymphoblastic leukemia 2015 multicenter study].
Chinese Children′s Cancer Group Acute Lymphoblastic Leukemia 2015 Study Group
Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1002-1010. PubMed ID: 36207846
[No Abstract] [Full Text] [Related]
32. Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database.
Kim JS; Liu Y; Ha KH; Qiu H; Rothwell LA; Kim HC
Cancer Res Treat; 2020 Oct; 52(4):1262-1272. PubMed ID: 32599988
[TBL] [Abstract][Full Text] [Related]
33. [Clinical features and prognosis of children with mature B-cell non-Hodgkin's lymphoma: an analysis of 28 cases].
Chen ZS; Zheng YZ; Chen YQ; Gao QL; Li J; Shen JZ
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jun; 20(6):470-474. PubMed ID: 29972121
[TBL] [Abstract][Full Text] [Related]
34. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
35. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
36. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Hüttmann A; Rekowski J; Müller SP; Hertenstein B; Franzius C; Mesters R; Weckesser M; Kroschinsky F; Kotzerke J; Ganser A; Bengel FM; La Rosée P; Freesmeyer M; Höffkes HG; Hertel A; Behringer D; Prange-Krex G; Griesshammer M; Holzinger J; Wilop S; Krohn T; Raghavachar A; Maschmeyer G; Brink I; Schroers R; Gaska T; Bernhard H; Giagounidis A; Schütte J; Dienst A; Hautzel H; Naumann R; Klein A; Hahn D; Pöpperl G; Grube M; Marienhagen J; Schwarzer A; Kurch L; Höhler T; Steiniger H; Nückel H; Südhoff T; Römer W; Brinkmann M; Ose C; Alashkar F; Schmitz C; Dürig J; Hoelzer D; Jöckel KH; Klapper W; Dührsen U
Ann Hematol; 2019 Apr; 98(4):897-907. PubMed ID: 30610279
[TBL] [Abstract][Full Text] [Related]
37. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Frontzek F; Ziepert M; Nickelsen M; Altmann B; Glass B; Haenel M; Truemper L; Held G; Bentz M; Borchmann P; Dreyling M; Viardot A; Kroschinsky FP; Metzner B; Staiger AM; Horn H; Ott G; Rosenwald A; Loeffler M; Lenz G; Schmitz N
Lancet Haematol; 2021 Apr; 8(4):e267-e277. PubMed ID: 33667420
[TBL] [Abstract][Full Text] [Related]
38. Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial.
Burke GAA; Vinti L; Kabickova E; Beishuizen A; Tacyildiz N; Uyttebroeck A; Kang HJ; Luisi F; Minard-Colin V; Burkhardt B; Tamegnon M; Sun S; Curtis M; Deshpande S; Nottage K; Howes A; Srinivasan S; Bhojwani D; Norris R; Cairo M
Blood Adv; 2023 Feb; 7(4):602-610. PubMed ID: 36541957
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and treatment outcomes of children and adolescents with aggressive mature B-cell lymphoma: a single-center analysis.
Jeon W; Koh YK; Kang S; Kim H; Koh KN; Im HJ
Blood Res; 2022 Mar; 57(1):41-50. PubMed ID: 35256548
[TBL] [Abstract][Full Text] [Related]
40. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G;
Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
